Warner-lambert Company

Mcneil-ppc, Inc.

Other

Neema Kulkarni

Albert F Sorg

Lori D Kumar

Sau-Hung Spence Leung

Robert S Leone

William Bess

Suhas H Ambike

Michael P Ramsay

Kanji Meghpara

Michael Schneider

Steven B Silbering

George E Tortarolo

W Michael Nichols

Hans Meyer-Wonnay

Nahid Sanii-Yahyai

Victor A Cruz

In various embodiments of the present invention, a capsule is provided including a hydrophobic inner layer and at least one hydrophilic outer layer. The hydrophobic layer may include a hydrophilic component such as an active pharmaceutical ingredient (API) which may be fully encapsulated, partially encapsulated or part of an adsorption complex. Such capsules experience no or minimal cracking or breaking in the outer layer.

Compositions with hydrophilic drugs in a hydrophobic medium

Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.

Fast dissolving orally consumable films

Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.

Fast dissolving orally consumable films containing a taste masking agent

A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.

Liquid pharmaceutical compositions

Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1

The present invention is directed to pharmaceutical compositions containing triprolidine and an ionic additive that improves the measured availability of the triprolidine in the tablet, as indicated by standard USP assay for triprolidine in pharmaceutical compositions. The invention also provides a process for producing compositions having improved triprolidine availability and a process for improving the performance of a pharmaceutical composition in a dissolution assay measuring triprolidine availability. The ionic additive can be, for example, an alkali metal salt, such as sodium chloride or potassium chloride.

Dissolution of triprolidine hydrochloride

Growing community of inventors

Randolph, NJ, United States of America

Neema Kulkarni